Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Serine is the major residue for ADP-ribosylation upon DNA damage

Luca Palazzo, Orsolya Leidecker, Evgeniia Prokhorova and 3 more

eLife · 2018 · CC BY

doi:10.7554/elife.34334

Abstract

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that synthesise ADP-ribosylation (ADPr), a reversible modification of proteins that regulates many different cellular processes. Several mammalian PARPs are known to regulate the DNA damage response, but it is not clear which amino acids in proteins are the primary ADPr targets. Previously, we reported that ARH3 reverses the newly discovered type of ADPr (ADPr on serine residues; Ser-ADPr) and developed tools to analyse this modification (Fontana et al., 2017). Here, we show that Ser-ADPr represents the major fraction of ADPr synthesised after DNA damage in mammalian cells and that globally Ser-ADPr is dependent on HPF1, PARP1 and ARH3. In the absence of HPF1, glutamate/aspartate becomes the main target residues for ADPr. Furthermore, we describe a method for site-specific validation of serine ADP-ribosylated substrates in cells. Our study establishes serine as the primary form of ADPr in DNA damage signalling.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

ADP-ribosylation (ADPr) is a reversible evolutionarily conserved posttranslational modification of proteins, which controls many critical cellular processes.

Poly(ADP-ribose) polymerases (PARPs) compose the major family of enzymes that catalyse the transfer of ADP-ribose unit(s) from NAD+ to protein substrates. Seventeen members of the PARP superfamily are encoded within the human genome, which are characterized by distinct structural domains, activities and involvement in a variety of cellular processes, including the DNA damage response (DDR). PARPs directly involved in DNA repair are PARP1, PARP2, and PARP3.

While PARP3 can attach only a single ADP-ribose unit on target proteins (MARylation), PARP1 and PARP2 can extend the initial ADPr event into long chains that remain attached on the proteins (Poly(ADP-ribosyl)ation, PARylation). PARP-dependent ADPr of these proteins is induced by binding of PARPs to DNA breaks, which produces timely and localised ADPr signals that control appropriate DDR mechanisms.

PARPs have previously been described to mainly target acidic residues (glutamates and aspartates; Glu and Asp, respectively) in proteins. However, we recently showed that serine (Ser) residues are also targets for PARP-dependent protein modification and that Ser ADP-ribosylation (Ser-ADPr) is involved in processes underlying genome stability and the DDR, in particular. Furthermore, we showed that the DNA damage responsive protein Histone PARylation Factor-1 (HPF1/C4orf27) forms complexes with either PARP1 or PARP2 and promotes the synthesis of Ser-ADPr on a variety of protein substrates. Finally, we discovered ARH3/ADPRHL2 as a hydrolase responsible for the specific reversal of Ser-ADPr in cells.

Our previous observations suggested that Ser-ADPr is a widespread form of ADPr in cells. Here, by using a combination of biochemical and cell biology approaches, we demonstrate that the bulk of ADPr synthesised in cultured mammalian cells is strictly dependent on HPF1 and that Ser-ADPr represents the most abundant form of ADPr after DNA damage in these cells.

Results and discussion

ADPr of proteins rapidly occurs to recruit and control activities of many crucial proteins involved in the repair of damaged DNA. The study of ADPr has been significantly hampered by technical limitations, such as the barriers to visualize all forms of cellular ADPr and the challenges in proteomics analyses. For example, until recently, only anti-PAR antibodies have been available, which can detect only the long PAR chains. However, recently a reagent specific for ADPr of any length (referred here as a pan-ADPr antibody) as well as a reagent specific for mono-ADPr have been developed and allowed us to follow protein ADPr events in cells upon DNA damage. We first exposed human osteosarcoma U2OS to the DNA damaging agent hydrogen peroxide (H2O2) and compared the ADPr pattern of control, ARH3 knock-out (KO), HPF1 KO and PARP1 KO cells (Figure 1A). In control cells, pan-ADPr signals after DNA damage revealed a number of modified proteins in the extract. The most easily identifiable signals relate to the modification of histone proteins as well as PARP automodification (Figure 1A). Both signals can also be recognised by the reagent that is specific for MARylation (referred here as a mono-ADPr antibody; Figure 1A). 2 hr after DNA damage the global ADPr signal is reduced to the levels comparable to untreated cells. However, importantly, the DNA damage-inducible ADPr is prevented in HPF1-depleted cells (Figure 1A), as we observed previously for specific histone substrates. An exception is the auto-modification of PARP1 that is characterized by relatively longer ADPr chains (although also at overall lower levels) when compared to control cells (Figure 1A), as noted previously. Expectedly, most of the global ADPr signal was abolished in PARP1 KO cells, as we showed previously for histone Ser-ADPr marks, confirming that PARP1 is the most active PARP involved in DDR (Figure 1A). In order to investigate whether the global pan-ADPr is truly dependent on HPF1, we tested two independent clones of HPF1 KO cells and observed comparable results with both cell lines (Figure 1B). These data suggest that global ADPr in response to DNA damage requires both HPF1 and PARP1.

As observed in our previous study, ARH3 KO cells already showed notably higher levels of ADPr proteins under unstimulated conditions when compared to control cells (Figure 1A–B). However, the difference in ADPr signal upon DNA damage was much more pronounced and allowed detection of a number of additional ADP-ribosylated protein bands in ARH3-deficient extracts that persisted for at least 2 hr. This was especially obvious for histone ADPr detected by the pan-ADPr reagent (Figure 1A–B).

Next, we used another DNA damaging agent, the alkylating agent methyl methanesulfonate (MMS). U2OS cells were treated with MMS, and then their recovery was analysed at 40’ and 120’ time points. Consistent with the observations for H2O2 treatment, most of the ADPr signal was HPF1-dependent and persisted in ARH3-deficient cells (Figure 1C).

In order to validate our observations in other cellular models, we next tested the human embryonic kidney (HEK) 293 cells. To confirm whether ADPr is HPF1-dependent in these cells, we challenged wild type and HPF1-depleted HEK293 cells with H2O2 (Figure 1D). Notably, HEK293 cells showed a number of ADP-ribosylated proteins detected by pan-ADPr antibody and modifications of most of these proteins were strictly dependent on HPF1 protein (Figure 1D).

The dependence of ADPr regulation on HPF1 and ARH3 suggests that Ser-ADPr is the dominant form of ADPr upon DNA damage. This is consistent with the data from recent proteomic analyses capable of detecting Ser-ADPr. However, proteomics studies based on hydroxylamine, which excludes ADPr mapping on residues other than the Glu and Asp, showed that modification of these residues is widespread in DDR. We reasoned that hydroxylamine could allow a direct and simple estimate of the abundance of the modification on Glu/Asp in the context of the global ADPr. Importantly, using defined substrates for both Ser-ADPr and Glu/Asp-ADPr, we showed by autoradiography that hydroxylamine does not remove ADPr from Ser residues (Figure 2A) while confirming the complete removal of ADPr from Glu/Asp (Figure 2B). Considering the above data (Figure 1) and previous studies that imply the predominance of Ser-ADPr upon DNA damage, we hypothesized that the loss of signal after hydroxylamine treatment would be minor in wild type cells. To test this, we incubated hydroxylamine with proteins extracted under denaturing conditions from both control (Figure 2C) and H2O2–treated (Figure 2D) cells and monitored the ADPr signal with the anti-pan-ADPr and anti-PAR antibodies. We observed no noticeable loss of either the global ADPr or PARylation signal in DNA-damaged cells (Figure 2D) and only a moderate reduction in untreated cells (Figure 2C), indicating that under these conditions Glu/Asp-ADPr is not abundant. In contrast, intriguingly, hydroxylamine completely abolished both the global ADPr and PAR signals on proteins extracted from HPF1 KO cells (Figure 2C–D), implying that in the absence of HPF1 virtually all the ADPr is on acidic residues. This cellular finding is in accordance with the well-established biochemical evidence that Asp and Glu are the prevalent target residues when in vitro ADPr reactions are performed without HPF1.

The above experiments demonstrate the abundance of Ser-ADPr by monitoring global ADPr level (Figure 1). To investigate this on a specific substrate, we analysed the level of Ser-ADPr on histone H2B. In our previous studies, we identified by mass spectrometry ADPr of H2B exclusively on Ser residues and showed that this modification is highly dependent on HPF1 in cells. Here, we set to investigate whether Ser-ADPr is the primary form of ADPr on histone H2B. To test this, we generated mammalian expression constructs where H2B was tagged with the Flag epitope as well as a version of Flag-tagged H2B where the main candidate ADPr site, Ser6 was mutated to alanine (S6A). Both wild type and S6A Flag-tagged H2B constructs were transiently transfected into control and HPF1-depleted HEK293 cells. Whilst the Flag-tagged wild type H2B was efficiently ADP-ribosylated upon H2O2 treatment in control cells, the H2B ADPr signal was completely abolished in HPF1 KO HEK293 cells, as shown in both whole cell extracts and Flag-immunoprecipitations (IP) (Figure 3A–B, respectively). In addition, the S6A mutant did not show any ADPr in both control and HPF1-depleted cells. These data demonstrate that Ser residue at position six is the main acceptor site of ADPr on H2B and confirm that this Ser-ADPr is HPF1-dependent.

Next, we used the same approach to confirm the main in vivo ADPr sites on histone H3. In our previous study, we detected H3 ADPr sites in cells on Ser10 and Ser28, so we prepared the constructs for the expression of the Flag-tagged H3 wild type protein, the H3 alanine mutants at Ser10 (S10A) and Ser28 (S28A), as well as the double mutant (S10A S28A). Flag-IP of the Flag-tagged proteins expressed in HEK293 cells and subsequent western blot against pan-ADPr revealed that the mutation of both Ser10 and Ser28 on H3 abolishes the DNA damage-induced H3 ADPr (Figure 4). Furthermore, we observed that in our conditions ADPr predominantly happens on the Ser10 site, while the mutation of Ser28 showed a small, but significant reduction of ADPr. In conclusion, the expression of wild type and Ser-ADPr mutants in HEK293 cells by this simple approach should allow the validation of Ser-ADPr sites for many other ADP-ribosylated candidate proteins involved in the DDR.

ADPr is unique among posttranslational modifications for its exceptional chemical versatility in modifying a variety of substrate amino acids. Glu, Asp, Lys, Arg and Ser have been indicated as the major ADPr target residues by recent proteomics studies, some of which, however, employ sub-optimal approaches that may lead to misassignment of ADPr specificities. Thus, the attention is currently shifting from mere identification of ADPr sites to the elucidation of the biological pathways in which a form of ADPr plays a major role. Our discovery of Ser-ADPr in 2016 has fuelled the rapid progress in the field, which has already resulted in the identification of the ‘eraser’ of Ser-ADPr. Our computational reanalysis of a published ADPr dataset; ProteomeXchange ID: PXD004245) showed that Ser-ADPr is a widespread modification. This has stimulated the current study, in which we address the abundance of Ser-ADPr in cells. Our findings show that in endogenous wild type cells Ser-ADPr is the primary form of ADPr upon DNA damage. This is consistent with the data from an independent study, in which an unbiased proteomics technology showed that the vast majority of ADPr localises on Ser residues. Importantly, our data indicate that Asp and Glu are the main targets of ADPr in PARP1-dependent, but HPF1-independent DNA damage signalling. This extends the concept of the ‘switching’ of PARP1 amino acid specificity to the cellular context. Future studies are needed to unravel the physiological and pathological conditions controlled by Ser-ADPr and Asp/Glu-ADPr.

In conclusion, the discovery of Ser-ADPr as well as the recent discoveries of reversible ADPr of DNA have added considerable depth to our understanding of the function and versatility of ADPr signalling in the cell, and raise the possibility that there may be other unique cellular and molecular processes regulated by ADPr.

Antibodies

Anti-PAR polyclonal antibody (4336-BPC-100, RRID:AB_2721257; rabbit) was purchased from Trevigen (Gaithersburg, MD, U S ) and used at 1:1000 dilutions. Monoclonal anti-pan-ADPr (MABE1016, RRID:AB_2665466), monoclonal anti-mono-ADPr (MABE1076, RRID:AB_2665469) and polyclonal anti-histone H3 (07–690, RRID:AB_417398) rabbit antibodies were purchased from Millipore (Billerica, MA, US ) and used at 1:1500, 1:1000 and 1:2000 dilutions, respectively. Rabbit polyclonal anti-ARH3/ADPRHL2 (HPA027104, RRID:AB_10601330) was purchased from Atlas Antibodies (Stockholm, Sweden) and used at 1:1000 dilution. Rabbit monoclonal anti-PARP1 (ab32138, RRID:AB_777101) was purchased from Abcam (Cambridge, UK) and used at 1:1000 dilution. Custom-made rabbit polyclonal HPF1 antibody was used as described (1:1000). Anti-Flag M2 agarose affinity gel (A2220, RRID:AB_10063035) and anti-Flag HRP-conjugated (A8592, RRID:AB_439702; used at 1:5000 dilution) mouse monoclonal antibodies were purchased from Sigma-Aldrich (St. Louis, MO, US). Immunoblots were performed as previously described.

Cell lines

Human U2OS osteosarcoma (ATCC HTB-96, RRID:CVCL_0042) and HEK293 (ATCC CRL-3216, RRID:CVCL_0063) cells were acquired from ATCC, identity was confirmed by STR profiling, and absence of mycoplasma contamination confirmed by MycoAlert Mycoplasma Detection Kit. Cells were cultured as previously described. Generation of KO cell lines was previously described.

Plasmid constructs

Full-length human histones H2B and H3.1 cDNA were cloned into the pDONR221 vector (Thermo Fisher Scientific; Waltham, MA, US). Ser to Ala point mutations were produced in pDONR221-H2B and pDONR-H3.1 by site directed mutagenesis. Mammalian expression constructs expressed H2B and H3.1 proteins with the C-terminal 3xFlag tag.

Transfection

Transient DNA transfections in HEK293 cells were performed with Polyfect (QIAGEN; Venlo, Netherlands) for 24 hr.

Induction of DNA damage, preparation of cell extracts

For MMS treatment, cells were damaged with 2 mM MMS (Sigma-Aldrich; St. Louis, MO, US) for 1 hr. In case of H2O2, cells were damaged with 2 mM H2O2 (Sigma-Aldrich; St. Louis, MO, US) for 10 min. Cells were lysed as previously described in the following buffer: 50 mM Tris-HCl pH 8.0, 100 mM NaCl, and 1% Triton X-100. Immediately before lysing the cells, the lysis buffer was supplemented with 5 mM MgCl2, 1 mM DTT, proteases and phosphatases inhibitors (Roche; Basel, Switzerland), 1 μM ADP-HPD (Calbiochem, La Jolla, CA), and 1 μM Olaparib (Cayman Chemical, Ann Arbor, MI). After the cell pellet was resuspended in the supplemented lysis buffer, Benzonase (Sigma-Aldrich; St. Louis, MO, US) was added.

Hydroxylamine experiments

Cell pellets were resuspended in SDS lysis buffer (10 mM HEPES pH 8.0, 2 mM MgCl2, 1% SDS, 250 U Universal Nuclease (Pierce; Waltham, MA, US), 1 x protease inhibitor (Roche; Basel, Switzerland) and briefly sonicated. BCA assay (Pierce; Waltham, MA, US) was used to determine the protein concentration. 30 µg damaged or 50 µg non-damaged cell were treated with 1 M NH2OH (hydroxylamine; Sigma-Aldrich; St. Louis, MO, US) for 3 hr at room temperature or left untreated. After the treatment, extracts were neutralized with 0.3% HCl and mixed with 4x SDS Loading buffer (Invitrogen; Calrsbad, CA, US) containing 100 mM DTT, followed by immunoblotting as described above.

In vitro ADP-ribosylation and detection by autoradiography

In vitro ADP-ribosylation reactions were performed as previously described. Reactions were stopped by Olaparib (2 μM final concentration) and then incubated with or without 1 M NH2OH for 3 hr before being detected by autoradiography. The molarity of HPF1 proteins used in the reactions were 1 μM, PARP1 was 0.1 μM and PARP1 E988Q 4 μM. The synthetic H3 peptide substrates were 3 μg per condition.

References 33

  1. 1.

    Barkauskaite E, Jankevicius G, Ahel I. Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation. Molecular Cell. 2015;58:935-946.

    Not in our library10.1016/j.molcel.2015.05.007

  2. 2.

    Bilan V, Leutert M, Nanni P, Panse C, Hottiger MO. Combining higher-energy collision dissociation and electron-transfer/higher-energy collision dissociation fragmentation in a product-dependent manner confidently assigns proteomewide ADP-ribose acceptor sites. Analytical Chemistry. 2017;89:1523-1530.

    Not in our library10.1021/acs.analchem.6b03365

  3. 3.
  4. 4.

    Bonfiglio JJ, Colby T, Matic I. Mass spectrometry for serine ADP-ribosylation? Think o-glycosylation! Nucleic Acids Research. 2017b;45:6259-6264.

    Not in our library10.1093/nar/gkx446

  5. 5.

    Crawford K, Bonfiglio JJ, Mikoč A, Matic I, Ahel I. Specificity of reversible ADP-ribosylation and regulation of cellular processes. Critical Reviews in Biochemistry and Molecular Biology. 2018;53:64-82.

    Not in our library10.1080/10409238.2017.1394265

  6. 6.

    D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. The Biochemical Journal. 1999;342 (Pt 2):249-268.

    Not in our library10.1042/bj3420249

  7. 7.

    Daniels CM, Ong SE, Leung AK. The promise of proteomics for the study of ADP-ribosylation. Molecular Cell. 2015;58:911-924.

    Not in our library10.1016/j.molcel.2015.06.012

  8. 8.

    Dölle C, Ziegler M. ADP-ribosylation of DNA moving into focus. The FEBS Journal. 2017;284:3999-4001.

    Not in our library10.1111/febs.14326

  9. 9.
  10. 10.

    Gagné JP, Ethier C, Defoy D, Bourassa S, Langelier MF, Riccio AA, Pascal JM, Moon KM, Foster LJ, Ning Z, Figeys D, Droit A, Poirier GG. Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs. DNA Repair. 2015;30:68-79.

    Not in our library10.1016/j.dnarep.2015.02.004

  11. 11.
  12. 12.

    Gibson BA, Conrad LB, Huang D, Kraus WL. Generation and characterization of recombinant antibody-like ADP-ribose binding proteins. Biochemistry. 2017;56:6305-6316.

    Not in our library10.1021/acs.biochem.7b00670

  13. 13.

    Gupte R, Liu Z, Kraus WL, PARPs KWL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes & Development. 2017;31:101-126.

    Not in our library10.1101/gad.291518.116

  14. 14.
  15. 15.

    Langelier MF, Pascal JM. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Current Opinion in Structural Biology. 2013;23:134-143.

    Not in our library10.1016/j.sbi.2013.01.003

  16. 16.
  17. 17.

    Leidecker O, Bonfiglio JJ, Colby T, Zhang Q, Atanassov I, Zaja R, Palazzo L, Stockum A, Ahel I, Matic I. Serine is a new target residue for endogenous ADP-ribosylation on histones. Nature Chemical Biology. 2016;12:998-1000.

    Not in our library10.1038/nchembio.2180

  18. 18.

    Leung AK. SERious surprises for ADP-Ribosylation specificity: HPF1 switches PARP1 specificity to ser residues. Molecular Cell. 2017;65:777-778.

    Not in our library10.1016/j.molcel.2017.02.012

  19. 19.

    Lüscher B, Bütepage M, Eckei L, Krieg S, Verheugd P, Shilton BH. ADP-Ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chemical Reviews. 2018;118:1092-1136.

    Not in our library10.1021/acs.chemrev.7b00122

  20. 20.
  21. 21.

    Martin-Hernandez K, Rodriguez-Vargas JM, Schreiber V, Dantzer F. Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Seminars in Cell & Developmental Biology. 2017;63:92-101.

    Not in our library10.1016/j.semcdb.2016.09.009

  22. 22.

    Matic I, Ahel I, Hay RT. Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites. Nature Methods. 2012;9:771-772.

    Not in our library10.1038/nmeth.2106

  23. 23.

    Moss J, Yost DA, Stanley SJ. Amino acid-specific ADP-ribosylation. The Journal of Biological Chemistry. 1983;258:6466-6470.

    Not in our library

  24. 24.
  25. 25.

    Palazzo L, Mikoč A, Ahel I. ADP-ribosylation: new facets of an ancient modification. The FEBS Journal. 2017a;284:2932-2946.

    Not in our library10.1111/febs.14078

  26. 26.

    Palazzo L, James DI, Waddell ID, Ahel I. Studying Catabolism of Protein ADP-Ribosylation. Methods in Molecular Biology. 2017b;1608:415-430.

    Not in our library10.1007/978-1-4939-6993-7_26

  27. 27.

    Sharifi R, Morra R, Appel CD, Tallis M, Chioza B, Jankevicius G, Simpson MA, Matic I, Ozkan E, Golia B, Schellenberg MJ, Weston R, Williams JG, Rossi MN, Galehdari H, Krahn J, Wan A, Trembath RC, Crosby AH, Ahel D, Hay R, Ladurner AG, Timinszky G, Williams RS, Ahel I. Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. The EMBO Journal. 2013;32:1225-1237.

    Not in our library10.1038/emboj.2013.51

  28. 28.

    Talhaoui I, Lebedeva NA, Zarkovic G, Saint-Pierre C, Kutuzov MM, Sukhanova MV, Matkarimov BT, Gasparutto D, Saparbaev MK, Lavrik OI, Ishchenko AA. Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro. Nucleic Acids Research. 2016;44:9279-9295.

    Not in our library10.1093/nar/gkw675

  29. 29.

    Tao Z, Gao P, Liu HW. Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications. Journal of the American Chemical Society. 2009;131:14258-14260.

    Not in our library10.1021/ja906135d

  30. 30.

    Vivelo CA, Leung AK. Proteomics approaches to identify mono-(ADP-ribosyl)ated and poly(ADP-ribosyl)ated proteins. Proteomics. 2015;15:203-217.

    Not in our library10.1002/pmic.201400217

  31. 31.

    Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, Ahel I, Chang P. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nature Communications. 2014;5:4426.

    Not in our library10.1038/ncomms5426

  32. 32.

    Zhang Y, Wang J, Ding M, Yu Y. Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. Nature Methods. 2013;10:981-984.

    Not in our library10.1038/nmeth.2603

  33. 33.

    Zhen Y, Zhang Y, Yu Y. A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer. Cell Reports. 2017;21:2326-2337.

    Not in our library10.1016/j.celrep.2017.10.106

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.